Published On: 11-14-2022 | Published In: Dissertation Defense, Event, Featured News, Speakers and Events,
Phenotypic and genotypic heterogeneity are characteristic features of cancer patients. To tackle patients’ heterogeneity, immune checkpoint inhibitors (ICIs) represent one of the most promising therapeutic approaches. However, approximately 50% of cancer patients that are eligible for treatment with ICIs will not respond well, which motivates the exploration of immunotherapy in combination with either targeted treatments
Read MorePublished On: 09-06-2022 | Published In: Dissertation Defense, Event, Featured News, Speakers and Events,
Immune checkpoints are a normal part of the immune system. It engages when proteins on the surface of immune cells called T cells recognize and bind to partner proteins on other cells, such as some tumor cells. Immune based therapies such as ICIs work by blocking checkpoint proteins from binding with their partner proteins. This
Read MoreJinpu Li
01-26-2023
4:00PM-4:30PM
S203 Memorial Union
01-26-2023
3:30PM-4:00PM
S203 Memorial Union
12-02-2022
3:00PM-4:00PM
Zoom
11-17-2022
1:00PM-2:00PM
Zoom
Activities include journal clubs, colloquium series, ideas labs, and team building.